In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump

Antimicrob Agents Chemother. 2003 Jan;47(1):390-4. doi: 10.1128/AAC.47.1.390-394.2003.

Abstract

Enrofloxacin treatment of chickens infected with fluoroquinolone(FQ)-sensitive Campylobacter promoted the emergence of FQ-resistant Campylobacter mutants which propagated in the intestinal tract and recolonized the chickens. The recovered isolates were highly resistant to quinolone antibiotics but remained susceptible to non-FQ antimicrobial agents. Specific single-point mutations in the gyrA gene and the function of the CmeABC efflux pump were linked to the acquired FQ resistance. These results reveal that Campylobacter is hypermutable in vivo under the selection pressure of FQ and highlight the need for the prudent use of FQ antibiotics.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Anti-Infective Agents / pharmacology*
  • Anti-Infective Agents / therapeutic use
  • Campylobacter Infections / drug therapy
  • Campylobacter jejuni / drug effects
  • Campylobacter jejuni / genetics*
  • Chickens
  • Ciprofloxacin / pharmacology
  • DNA Gyrase / drug effects
  • DNA Gyrase / genetics*
  • Drug Resistance, Microbial / genetics*
  • Enrofloxacin
  • Fluoroquinolones*
  • Microbial Sensitivity Tests
  • Mutation
  • Nalidixic Acid / pharmacology
  • Quinolones / pharmacology*
  • Quinolones / therapeutic use

Substances

  • Anti-Infective Agents
  • Fluoroquinolones
  • Quinolones
  • Nalidixic Acid
  • Enrofloxacin
  • Ciprofloxacin
  • DNA Gyrase